News Headlines Article

What an emerging drug company is doing to disrupt depression — podcast
San Francisco Business Times

Major depressive disorder — the persistent, intense sadness that most people know simply as depression — is pervasive: One estimate pegs 7 percent of Americans over 18 as having had an episode.

The condition typically is treated with antidepressants as well as psychotherapy and lifestyle changes, since alcohol or drug abuse, medical conditions such as cancer and other types of medication can trigger events.

BlackThorn Therapeutics Inc. thinks it has another way. Its drug, called BTRX-246040, started a mid-stage clinical trial in July in adults with the neurobehavioral condition. Patients take the drug once a day for eight weeks. The study is seeking to identify subtypes of major depressive disorder that may be most responsive to BTRX-246040 and similar drugs.